Bicycle Therapeutics (NASDAQ:BCYC) Coverage Initiated by Analysts at Stephens

Stephens assumed coverage on shares of Bicycle Therapeutics (NASDAQ:BCYC) in a report published on Friday, MarketBeat.com reports. The brokerage issued an equal weight rating and a $25.00 price objective on the stock.

Several other equities analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Oppenheimer reaffirmed an “outperform” rating and set a $48.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, August 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $35.00 price target on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $32.00 price objective on shares of Bicycle Therapeutics in a report on Monday, September 16th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Bicycle Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.13.

Bicycle Therapeutics Stock Performance

Bicycle Therapeutics stock opened at $24.32 on Friday. The firm has a market cap of $1.16 billion, a P/E ratio of -7.39 and a beta of 0.89. The business’s fifty day moving average is $24.44 and its two-hundred day moving average is $23.17. Bicycle Therapeutics has a 52 week low of $12.54 and a 52 week high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. The company had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business’s revenue was down 50.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.26) earnings per share. On average, equities research analysts predict that Bicycle Therapeutics will post -3.01 earnings per share for the current year.

Insider Transactions at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 3,212 shares of the company’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total transaction of $71,499.12. Following the completion of the transaction, the chief executive officer now directly owns 380,864 shares of the company’s stock, valued at $8,478,032.64. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 4,584 shares of company stock valued at $102,040 over the last three months. Company insiders own 8.50% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

Hedge funds have recently made changes to their positions in the business. Assetmark Inc. acquired a new stake in shares of Bicycle Therapeutics in the third quarter valued at approximately $34,000. GAMMA Investing LLC lifted its position in shares of Bicycle Therapeutics by 105.1% in the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after buying an additional 1,038 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Bicycle Therapeutics by 69.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after buying an additional 2,918 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Bicycle Therapeutics in the second quarter valued at approximately $206,000. Finally, Crossmark Global Holdings Inc. bought a new position in shares of Bicycle Therapeutics during the third quarter worth approximately $257,000. 86.15% of the stock is owned by institutional investors and hedge funds.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.